Douglas has a robust portfolio of innovative projects in various therapeutic areas. We’re seeking co-development partners with complementary expertise and resources to accelerate the development and commercialisation of these promising therapies.
Innovation is at the heart of everything we do at Douglas. Our experience in product development has enabled us to create a portfolio of successful therapies that have made a real difference in patients’ lives.
We offer a unique blend of expertise, resources, and a proven track record of success, making us an ideal partner for co-development ventures. Here’s what sets us apart.
With over 58 years of experience in pharmaceutical development, manufacturing, and commercialisation, we possess the knowledge and insights to navigate the complexities of the healthcare landscape.
The scientists and formulators who developed our products are still on the team at Douglas. This continuity provides an unparalleled depth of understanding and ensures that the original vision for each product is maintained and enhanced.
Our GMP-certified manufacturing plant and advanced research laboratories, and access to clinical research trial teams provide the infrastructure necessary to support projects from concept to commercialisation.
We have experience with regulators across the globe and have established a robust distribution network in 90 countries.
Douglas is renowned for adherence to the highest international quality standards, ensuring the safety and efficacy of all our products.
We understand that every project is unique. We offer flexible partnership models tailored to your specific needs and objectives.
We’re committed to building long-term, mutually beneficial partnerships based on trust, transparency, and open communication.
505(j) Complex Generic Pipeline
Douglas has several projects in the pre-formulation or formulation development stage.
Douglas specialises in specialty generic product development such as soft-gelatin capsules that have technical, clinical or IP complexity.
505(b)(2) Pipeline
Douglas specialises in the development of 505(b)(2) alternative formulation products to meet unmet needs in populations of paediatric, geriatric and patients with swallowing difficulties.
We are open to collaboration on these oral liquid opportunities focusing on the US market.
